Using Cogstate Digital Assessments to Identify Cognitive Impairment in AD Trials

Cogstate digital cognitive assessments have been used extensively as rapid and reliable screening assessments in a range of clinical indications, including Alzheimer’s Disease (AD), Mild Cognitive Impairment, and Dementia.

The tests are well-validated assessment options for study teams looking for an efficient and effective way to identify cognitive impairment in all phases of AD clinical trials.

From among Cogstate’s tests, the Cogstate Brief Battery (CBB) and International Shopping List Test (ISLT) are commonly used to assess cognitive impairment and change related to AD.

Please fill out the form below to download the Literature Spotlight and learn more.

Back to Fact Sheets